We use cookies on our website to track and enhance your user experience. For more information or to update your cookie settings, please refer to our privacy policy.

Accept Decline

SureSeq myPanel™ NGS Custom Prostate Cancer Panel

Applications:
Product types:

Choose your ideal prostate cancer NGS panel from our range of fully optimised NGS panel content. Simply mix and match the genes or individual exons you require and get the most out of your sequencing runs.

Find out more

For more information about any OGT product or service, please contact us.

Email: contact@ogt.com
Phone: +44 (0)1865 856800 (US: 914 467 5285)

Details

 

Prostate cancer is now the second leading cause of cancer in men, with recent genome-wide studies helping to clarify the genetic basis of this common but complex disease1. Many of these studies have reinforced the importance of homologous end repair genes including: ATM, BRCA1, BRCA2 and PALB2, in the mechanism of prostate cancer development. Mutations in these genes result in cells having to repair lesions through other non-conservative mutagenic mechanisms.

 SureSeq myPanel offers:

  • Hybridisation-based enrichment delivering unparalleled coverage uniformity — detect low frequency prostate cancer variants consistently with confidence and minimise the requirement for supplementary fill-in with Sanger sequencing
  • Pre-optimised panels that meet your technical requirements and work with your samples— no more lengthy in-house optimisation, decreasing assay development time
  • Bespoke panel content — sequence only what’s relevant for your cancer research, increase throughput and save on sequencing reagents
  • Panel content designed with experts and from current literature to target all relevant regions including intronic and splice sites — get the most comprehensive insight into disease-driving mutations

Choose your ideal prostate cancer NGS panel from our range of fully optimised NGS panel content. Simply mix and match the genes or individual exons you require and get the most out of your sequencing runs. Use in conjunction with the SureSeq FFPE DNA Repair Mix* for improved NGS library yields, %OTR (on target rate) and mean target coverage from challenging FFPE derived samples.

 

Let's talk about panel content >

Superior Coverage Uniformity

A number of genetic factors have been found that increase prostate cancer risk, including heritable mutations in the genes BRCA1 and BRCA2. BRCA1 is a key player in cellular control systems, having been linked to DNA damage response and repair, transcriptional regulation and chromatin modelling2, while BRCA2 function is linked to DNA recombination and repair processes, being of particular importance in the regulation of RAD51 activity.

Figure 1a, illustrates the superior uniformity of coverage of key exons of BRCA1, and Figure 1b, BRCA2 from an FFPE sample.

Figure 1a

Figure 1a

Figure 1b

Figure 1bFigure 1a. BRCA1 exon 9 and 10 coverage. Figure 1b. BRCA2 exon 11 coverage. Depth of coverage per base (grey). Targeted region (green). Gene coding region as defined by RefSeq (blue). GC percentage (red).

PALB2 is a BRCA2 binding protein and the BRCA2-PALB2 interaction is essential for BRCA2-mediated DNA repair. Recently it has been shown that correct PALB2 function is necessary for the homologous recombination repair via interaction with BRCA1, revealing that PALB2 is actually a linker between BRCA1 and BRCA23. The ATM gene, located on chromosome 11q 22–23, includes 66 exons with a 9168 base pair coding sequence, and encodes a PI3K-related protein kinase (PIKK) that helps maintain genomic integrity. The PI3K-AKT-mTOR oncogenic pathway is frequently enhanced in prostate cancer playing a vital role in development and maintenance4.

Figures 2 and 3 illustrate the excellent uniformity of coverage of key exons of PALB2 and ATM, respectively.

Figure 2a

Figure 2a

Figure 2b

Figure 2b

Figure 3a

Figure 3a

Figure 3b

Figure 3bFigures 3a and 3b. Illustration of the excellent uniformity of coverage of PALB2 exons 5 (2a) and 13 (2b) and ATM exons 45 (3a) and 62 (3b). Depth of coverage per base (grey). Targeted region (green). Gene coding region as defined by RefSeq (blue). GC percentage (red).

Getting started with your next SureSeq myPanel Custom Cancer Panel could not be simpler. 

Select from any of the following myPanel Prostate Cancer whole gene or exonic content below:

ATMBRCA1BRCA2PALB2

 

SureSeq myPanel

Talk to us about your custom breast cancer NGS requirements and let our expertise work in helping you to advance your cancer research…

Let's talk about panel content >

Ordering Information

ProductContentsCat. No.Price
SureSeq myPanel NGS Custom Prostate Cancer Panels Enrichment baits; SureSeq Interpret Software Various Get a quote
SureSeq FFPE DNA Repair Mix* Enzyme, mix and buffers sufficient for 16 FFPE DNA samples 500079 Get a quote
SureSeq NGS Library Preparation Kit (16) Bundle of 1 x library preparation kit (16) containing adaptors, PCR primers and enzymes sufficient for 16 samples and 1 x SureSeq NGS Index Kit – Collection A 500070 Get a quote
SureSeq NGS Library Preparation Kit (48)  Bundle of 3 x library preparation kit (16), containing adaptors, PCR primers and enzymes sufficient for 48 samples and 1 x SureSeq NGS Index Kit – Collection B 500073 Get a quote
SureSeq NGS Index Kit - Collection A (16) 16 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (16)] 500071 Get a quote
SureSeq NGS Index Kit - Collection B (48) 48 different indexes, each sufficient for 4 samples [included with SureSeq NGS Library Preparation Kit (48)] 500072 Get a quote
Dynabeads™ M270 Streptavidin, 2ml Sample capture beads, sufficient for 20 samples 500080** Get a quote
AMPure® XP beads, 10ml Sample purification beads, sufficient for 16 samples 500081**  Get a quote

*The SureSeq FFPE DNA Repair Mix can only be purchased in conjunction with SureSeq NGS panels, not as a standalone product.

** Only for use with SureSeq NGS panels

References

  1. Thoma, C, (2015) The complex relationships of malignant cells in lethal metastatic castration-resistant disease, Nature Reviews Urology 12, 237
  2. Castro, E. et al, (2012) The role of BRCA1 and BRCA2 in prostate cancer. Asian Journal of Andrology, 14 (3):409-414.
  3. Pakkanen, S. et al, (2009) PALB2 variants in hereditary and unselected Finnish Prostate cancer cases. Journal of Negative Results in BioMedicine, 8 (1).
  4. Angèle, S. et al, (2004). ATM polymorphisms as risk factors for prostate cancer development. British Journal of Cancer, 91(4): 783–787.

 

SureSeq: For research use only; not for use in diagnostic procedures.

Resources

Catalogue

Product profile

Lab Programme

Brochure

Application note

Gene list

Poster

Flyer

White paper

Handbook

<  Return to products Back to top ↑